Outcomes and quality of life in patients receiving durable left ventricular assist device with biventricular support

Abstract

AbstractBackgroundPatients requiring biventricular support (BIVAD) face higher morbidity than those undergoing durable left ventricular assist device (LVAD) implantation alone. The goal of the current study was to evaluate quality of life (QOL) of patients with LVAD therapy in the modern era, stratified by use of biventricular support.MethodsAll patients undergoing LVAD at our center were reviewed between October 2017 and September 2021. Patients were stratified by perioperative use of BIVAD. Patients were administered a telephone survey consisting of the Kansas City Cardiomyopathy Questionnaire (KCCQ‐12) as well as free‐responses regarding satisfaction surrounding their operation. Outcomes included survival, KCCQ‐12 metrics, and thematic analysis of free response questions.Results92 patients were identified, of whom 26 (28%) received BIVAD support. BIVAD patients had more preoperative ECMO use (54% vs. 12%, p < 0.001) and lower INTERMACS scores (Category 1: 46% vs. 14%, p = 0.001). Three‐year survival was 73.8% among LVAD‐alone patients and 50.1% among BIVAD patients (log‐rank p = 0.022). Median composite KCCQ‐12 score was 78 (57–88). No differences in composite or any component scores were noted between groups. 76% of patients report they would be moderately or extremely like to go through surgery again if given repeat choice. The most common themes expressed were overall gratitude (24%) and disappointment with device‐related restrictions (20%).ConclusionsPatients requiring BIVAD therapy have more advanced shock, longer associated hospital courses, and lower long‐term survival. However, those that survive enjoy similar overall quality of life, and many endorse positive outlooks on their surgical course. Continued assessments of quality of life are important in providing patient‐centered LVAD care.